Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, Nuala McCabe et al.
Background: Previously we identified a DNA damage response-deficient (DDRD) molecular subtype within breast cancer. A 44-gene assay identifying this subtype was validated as predicting benefit from DNA-damaging chemotherapy. This subtype was defined by interferon signaling. In this study, we address...
Eileen E. Parkes, Richard D. Kennedy
UNLABELLED: : High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying defects in the important DNA repair pathway of homologous recombination. Given the action of poly(ADP-ribose) polymerase (PARP) inhibitors in targeting tumors with deficienc...
Priyanka Duttagupta, Kiranj Chaudagar, Sweta Sharma Saha, Kaela Bynoe et al.
Abstract While immune checkpoint blockade (ICB) targeting CTLA-4 and PD-1/PD-L1 has shown remarkable success across a wide range of malignancies, the majority of prostate cancer (PC) patients do not demonstrate clinically meaningful responses to these therapies. Therefore, there is a critical unmet ...